Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO)MICVO combats solid tumors ...
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for ...
Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).
Pyxis Oncology had cash and cash equivalents, including restricted cash and short-term investments of $157.2 million. Pyxis says that its current cash, cash equivalents, and short-term investments ...
Key Insights The considerable ownership by retail investors in Pyxis Oncology indicates that they collectively have ...
Pyxis Oncology (NASDAQ:PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer (PFE) extended the recent winning streak into the fifth consecutive session, ...
Antibody drug conjugates, or ADCs, are picking up momentum. Of the 11 drugs in this class that have been approved by the FDA, six have reached the market in the last two years. Meanwhile, new ADC ...
In this episode of Capital Link's Trending News Webinar Series, we are joined by Eddie Valentis, Chairman and CEO of Pyxis Tankers (NASDAQ:PXS), reported strong Q3 2025 charter co ...
A mediocre charter rate environment for product tankers and dry bulk carriers impacted Pyxis Tankers' financial results in ...
Any time a business conference producer approaches the day when all the speakers and attendees get on airplanes and fly to the venue, things change fast. A speaker cancels and has to be replaced at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback